PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 260 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $24 | -100.0% | 637 | -30.4% | 0.00% | – |
| Q3 2022 | $48,000 | -21.3% | 915 | -14.0% | 0.00% | – |
| Q2 2022 | $61,000 | -18.7% | 1,064 | +8.2% | 0.00% | – |
| Q1 2022 | $75,000 | +29.3% | 983 | +0.7% | 0.00% | – |
| Q4 2021 | $58,000 | -10.8% | 976 | -16.2% | 0.00% | – |
| Q3 2021 | $65,000 | -4.4% | 1,165 | +2.8% | 0.00% | – |
| Q2 2021 | $68,000 | -6.8% | 1,133 | +7.9% | 0.00% | – |
| Q1 2021 | $73,000 | +17.7% | 1,050 | +1.3% | 0.00% | – |
| Q4 2020 | $62,000 | +14.8% | 1,037 | +14.7% | 0.00% | -100.0% |
| Q3 2020 | $54,000 | +237.5% | 904 | +200.3% | 0.00% | – |
| Q2 2020 | $16,000 | +33.3% | 301 | -17.1% | 0.00% | – |
| Q1 2020 | $12,000 | +33.3% | 363 | +81.5% | 0.00% | – |
| Q4 2019 | $9,000 | +12.5% | 200 | 0.0% | 0.00% | – |
| Q3 2019 | $8,000 | +33.3% | 200 | +22.7% | 0.00% | – |
| Q1 2019 | $6,000 | – | 163 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |